Practical NeurologyNew and Novel Potential Treatment for Alzheimer Disease Symptom Management

This study enrolled individuals with AD who had been on a stable dose of donezepil for
at least 90 days. They were then treated for 12 weeks with the addition of the
modulator of cholinergic neurotransmission AD101, or placebo. Those receiving AD101
had mean improvement of approximately 2 points on the Alzheimer Disease
Assessment Scale-Cognitive (ADAS-Cog) Subscale. Individuals who had continued donezepil plus
placebo showed declines on ADAS-Cog.